Warning is encouraged when administering these medications to older individuals due to heightened susceptibility to postural hypotension as well as the possible event of cannabis-induced delirium.In 2024, the U.S. Drug Enforcement Administration (DEA) indicated that they intend to reclassify cannabis being a Program III drug. This rescheduling will